Patents by Inventor Gilla Kaplan

Gilla Kaplan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9155502
    Abstract: Cerebral palsy impaired speech in children and adolescents are effectively treated by administration of a psychostimulant. Low doses of the psychostimulant significantly increases the percentage of correctly pronounced intelligible syllables or words and the ability to more intelligibly communicate. The improvement in speech persists after cessation of or prior to continued psychostimulant treatment.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: October 13, 2015
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • Publication number: 20150283122
    Abstract: A pharmaceutical intervention and therapeutic method for treating an apraxia of speech in children. The child can also be diagnosed with gait abnormalities or impairment autism, mental retardation and dyslexia. If the child demonstrates at least an 18 to 24 month development stage of either verbal development or non-verbal development, a therapeutic dose of a dopamine agonistic, particularly a nonlinear lower alkyl phenidate or dextro-threo-methylphenidate is administered to the child.
    Type: Application
    Filed: June 11, 2015
    Publication date: October 8, 2015
    Applicant: Gilrose Pharmaceuticals, LLC
    Inventors: BRUCE ROSEMAN, Gilla Kaplan
  • Publication number: 20140357668
    Abstract: Cerebral palsy impaired speech in children and adolescents are effectively treated by administration of a psychostimulant. Low doses of the psychostimulant significantly increases the percentage of correctly pronounced intelligible syllables or words and the ability to more intelligibly communicate. The improvement in speech persists after cessation of or prior to continued psychostimulant treatment.
    Type: Application
    Filed: August 20, 2014
    Publication date: December 4, 2014
    Inventors: Bruce Roseman, Gilla Kaplan
  • Publication number: 20140357667
    Abstract: Cerebral palsy impaired speech in children and adolescents are effectively treated by administration of a psychostimulant. Low doses of the psychostimulant significantly increases the percentage of correctly pronounced intelligible syllables or words and the ability to more intelligibly communicate. The improvement in speech persists after cessation of or prior to continued psychostimulant treatment.
    Type: Application
    Filed: August 6, 2014
    Publication date: December 4, 2014
    Inventors: Bruce Roseman, Gilla Kaplan
  • Patent number: 8883815
    Abstract: Cerebral palsy impaired speech in children and adolescents are effectively treated by administration of a psychostimulant. Low doses of the psychostimulant significantly increases the percentage of correctly pronounced intelligible syllables or words and the ability to more intelligibly communicate. The improvement in speech persists after cessation of or prior to continued psychostimulant treatment.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: November 11, 2014
    Assignee: Gilrose Pharmaceuticals, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • Publication number: 20140163070
    Abstract: Cerebral palsy impaired speech in children and adolescents are effectively treated by administration of a psychostimulant. Low doses of the psychostimulant significantly (p=0.0025) increases the percentage of correctly pronounced intelligible syllables or words and the ability to more intelligibly communicate (p=0.0309). The improvement in speech persists after cessation of or prior to continued psychostimulant treatment.
    Type: Application
    Filed: February 18, 2014
    Publication date: June 12, 2014
    Inventors: Bruce Roseman, Gilla Kaplan
  • Publication number: 20140051693
    Abstract: Cerebral palsy impaired speech in children and adolescents are effectively treated by administration of a psychostimulant. Low doses of the psychostimulant significantly increases the percentage of correctly pronounced intelligible syllables or words and the ability to more intelligibly communicate. The improvement in speech persists after cessation of or prior to continued psychostimulant treatment.
    Type: Application
    Filed: October 22, 2013
    Publication date: February 20, 2014
    Inventors: Bruce Roseman, Gilla Kaplan
  • Patent number: 5385901
    Abstract: Compounds of the structure ##STR1## wherein R is selected from the group consisting of hydrogen, alkyl radicals of 1-6 carbon atoms, the phenyl radical, and the benzyl radical; and wherein R' is selected from the group consisting of the phthalimido radical and the succinimido radical and of the structure ##STR2## wherein X is CH.sub.2 or C.dbd.O; R" is H, --CH.sub.2 CH.sub.3, --C.sub.6 H.sub.5, --CH.sub.2 C.sub.6 H.sub.5, --CH.sub.2 CH.dbd.CH.sub.2, or ##STR3## and hydrolysis products of said compounds wherein R" is H and the piperidino ring or both the piperidino and the imido ring are hydrolyzed are useful for the control of abnormal concentrations of TNF .alpha. manifested in septic shock, cachexia and HIV infection without substantially effecting the concentration of other cytokines.
    Type: Grant
    Filed: October 2, 1992
    Date of Patent: January 31, 1995
    Assignee: The Rockefeller University
    Inventors: Gilla Kaplan, Elisabeth P. Sampaio